Wellington Management Trims Zentalis Pharma Stake to 7.0%

TL;DR

**Wellington Management just cut its Zentalis Pharma stake to 7.0%.**

AI Summary

Wellington Management Group LLP, a major investment firm, filed an amended SC 13G/A on February 9, 2024, indicating a change in their ownership of Zentalis Pharmaceuticals, Inc. common stock as of December 29, 2023. This filing shows that Wellington now beneficially owns 4,147,749 shares, representing 7.0% of Zentalis's outstanding common stock. This is a decrease from their previous reported ownership, signaling a reduction in their stake in the pharmaceutical company.

Why It Matters

A significant institutional investor like Wellington reducing its stake could signal a shift in their outlook on Zentalis's future prospects, potentially influencing other investors' decisions.

Risk Assessment

Risk Level: medium — A large institutional investor reducing its stake can sometimes precede further stock price declines if other investors interpret it as a lack of confidence.

Analyst Insight

Investors considering Zentalis Pharmaceuticals, Inc. should investigate the reasons behind Wellington Management Group LLP's decision to reduce its stake, potentially looking for any new company developments or industry trends that might have influenced this move.

Key Numbers

• 4,147,749 — Shares Owned (The total number of Zentalis shares Wellington Management Group LLP beneficially owns as of December 29, 2023.)
• 7.0% — Ownership Percentage (The percentage of Zentalis Pharmaceuticals, Inc. common stock Wellington Management Group LLP now beneficially owns.)

Key Players & Entities

• Wellington Management Group LLP (company) — the reporting person decreasing its ownership
• Zentalis Pharmaceuticals, Inc. (company) — the subject company whose stock is being reported
• 4,147,749 (dollar_amount) — number of shares beneficially owned by Wellington Management Group LLP
• 7.0% (dollar_amount) — percentage of Zentalis Pharmaceuticals, Inc. common stock beneficially owned by Wellington Management Group LLP
• December 29, 2023 (date) — the date of the event requiring the filing
• February 9, 2024 (date) — the filing date of the SC 13G/A

Forward-Looking Statements

• Other institutional investors may review their positions in Zentalis Pharmaceuticals, Inc. following Wellington's reduced stake. (Zentalis Pharmaceuticals, Inc.) — medium confidence, target: Q1 2024

FAQ

Filing Documents

• SEC13G_Filing.htm (SC 13G/A) — 30KB
• 0000902219-24-000276.txt ( ) — 32KB

From the Filing

SC 13G/A 1 SEC13G_Filing.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 ) * Zentalis Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 98943L107 (CUSIP Number) December 29, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (the "Act") or otherwise subject to the liabilities of that section of the Act, but shall be subject to all other provisions of the Act (however, see the Notes.) CUSIP No. 98943L107 1. NAMES OF REPORTING PERSONS Wellington Management Group LLP 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [ ] (b) [ ] 3. SEC USE ONLY 4. CITIZENSHIP OR PLACE OF ORGANIZATION Massachusetts NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5. SOLE VOTING POWER 0 6. SHARED VOTING POWER 63,973 7. SOLE DISPOSITIVE POWER 0 8. SHARED DISPOSITIVE POWER 68,791 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 68,791 10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES [ ] 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 0.10% 12. TYPE OF REPORTING PERSON HC CUSIP No. 98943L107 1. NAMES OF REPORTING PERSONS Wellington Group Holdings LLP 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [ ] (b) [ ] 3. SEC USE ONLY 4. CITIZENSHIP OR PLACE OF ORGANIZATION Delaware NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5. SOLE VOTING POWER 0 6. SHARED VOTING POWER 63,973 7. SOLE DISPOSITIVE POWER 0 8. SHARED DISPOSITIVE POWER 68,791 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 68,791 10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES [ ] 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 0.10% 12. TYPE OF REPORTING PERSON HC CUSIP No. 98943L107 1. NAMES OF REPORTING PERSONS Wellington Investment Advisors Holdings LLP 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) [ ] (b) [ ] 3. SEC USE ONLY 4. CITIZENSHIP OR PLACE OF ORGANIZATION Delaware NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5. SOLE VOTING POWER 0 6. SHARED VOTING POWER 63,973 7. SOLE DISPOSITIVE POWER 0 8. SHARED DISPOSITIVE POWER 68,791 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 68,791 10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES [ ] 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 0.10% 12. TYPE OF REPORTING PERSON HC Item 1. (a) Name of Issuer Zentalis Pharmaceuticals, Inc. (b) Address of Issuer's Principal Executive Offices 1359 Broadway, Suite 801 New York, NY 10018 Item 2. (a) Name of Person Filing Wellington Management Group LLP Wellington Group Holdings LLP Wellington Investment Advisors Holdings LLP (b) Address of Principal Business Office or, if None, Residence c/o Wellington Management Company LLP 280 Congress Street Boston, MA 02210 (c) Citizenship Wellington Management Group LLP - Massachusetts Wellington Group Holdings LLP - Delaware Wellington Investment Advisors Holdings LLP - Delaware (d) Title of Class of Securities Common Stock (e) CUSIP Number 98943L107 Item 3. If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a: (a) [ ] Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o). (b) [ ] Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c). (c) [ ] Insurance Company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c). (d) [ ] Investment Company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8). (e) [ ] An investment adviser in accordance with Rule 240.13d-1(b)(1)(ii)(E); (f) [ ] An employee benefit plan or endowment fund in accordance with Rule 240.13d-1(b)(1)(ii)(F); (g) [X] A parent holding company or control person in accordance with Rule 240.13d-1(b)(1)(ii)(G); (h) [ ] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); (i) [ ] A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); (j) [ ] Group, in accordance with Rule 240.13d-

View Full Filing

View this SC 13G/A filing on SEC EDGAR